全文获取类型
收费全文 | 87706篇 |
免费 | 6886篇 |
国内免费 | 1783篇 |
专业分类
耳鼻咽喉 | 749篇 |
儿科学 | 2067篇 |
妇产科学 | 1109篇 |
基础医学 | 3944篇 |
口腔科学 | 4512篇 |
临床医学 | 8391篇 |
内科学 | 10849篇 |
皮肤病学 | 1525篇 |
神经病学 | 5173篇 |
特种医学 | 2125篇 |
外国民族医学 | 21篇 |
外科学 | 9021篇 |
综合类 | 15487篇 |
现状与发展 | 8篇 |
一般理论 | 4篇 |
预防医学 | 6273篇 |
眼科学 | 1504篇 |
药学 | 8565篇 |
162篇 | |
中国医学 | 8946篇 |
肿瘤学 | 5940篇 |
出版年
2024年 | 318篇 |
2023年 | 1435篇 |
2022年 | 2603篇 |
2021年 | 3597篇 |
2020年 | 3841篇 |
2019年 | 2940篇 |
2018年 | 2747篇 |
2017年 | 3030篇 |
2016年 | 3317篇 |
2015年 | 3064篇 |
2014年 | 6031篇 |
2013年 | 8167篇 |
2012年 | 5876篇 |
2011年 | 6185篇 |
2010年 | 5181篇 |
2009年 | 4478篇 |
2008年 | 3972篇 |
2007年 | 4193篇 |
2006年 | 3738篇 |
2005年 | 3203篇 |
2004年 | 2684篇 |
2003年 | 2321篇 |
2002年 | 1952篇 |
2001年 | 1596篇 |
2000年 | 1355篇 |
1999年 | 1081篇 |
1998年 | 897篇 |
1997年 | 821篇 |
1996年 | 686篇 |
1995年 | 613篇 |
1994年 | 567篇 |
1993年 | 480篇 |
1992年 | 398篇 |
1991年 | 356篇 |
1990年 | 270篇 |
1989年 | 271篇 |
1988年 | 246篇 |
1987年 | 224篇 |
1986年 | 206篇 |
1985年 | 259篇 |
1984年 | 205篇 |
1983年 | 136篇 |
1982年 | 176篇 |
1981年 | 140篇 |
1980年 | 122篇 |
1979年 | 113篇 |
1978年 | 63篇 |
1977年 | 58篇 |
1976年 | 47篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Ludger Grote MD PhD Lena Leissner MD Jan Hedner MD PhD Jan Ulfberg MD PhD 《Movement disorders》2009,24(10):1445-1452
Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society 相似文献
32.
Kathleen Hawker 《Annals of Indian Academy of Neurology》2009,12(4):221-225
B cells have recently been identified as an integral component of the immune system; they play a part in autoimmunity through antigen presentation, antibody secretion, and complement activation. Animal models of multiple sclerosis (MS) suggest that myelin destruction is partly mediated through B cell activation (and plasmablasts). MS patients with evidence of B cell involvement, as compared to those without, tend to have a worse prognosis. Finally, the significant decrease in new gadolinium-enhancing lesions, new T2 lesions, and relapses in MS patients treated with rituximab (a monoclonal antibody against CD20 on B cells) leads us to the conclusion that B cells play an important role in MS and that immune modulation of these cells may ameliorate the disease. This article will explore the role of B cells in MS and the rationale for the development of B cell–targeted therapeutics. MS is an immune-mediated disease that affects over 2 million people worldwide and is the number one cause of disability in young patients. Most therapeutic targets have focused on T cells; however, recently, the focus has shifted to the role of B cells in the pathogenesis of MS and the potential of B cells as a therapeutic target. 相似文献
33.
目的:观察喉罩全麻下行颈动脉狭窄的造影诊断及介入治疗术的临床效果。方法:择期DSA下颈动脉狭窄患者23例,年龄42-78岁,无明显肺部疾患及喉罩禁忌症患者,异丙酚(Pmpofol)泵入静脉全麻下插入喉罩完成手术,观察其不同时段的BP(MAP)、SpO2、HR、ECG(ST-Ⅱ)。结果:各时段的BP(MAP)、Sp02、HR、ECG(ST-Ⅱ)比较无显著性差异。结论:喉罩全麻在行颈动脉狭窄的造影诊断及介入治疗术的临床效果是肯定的。喉罩全麻颈动脉狭窄造影介入治疗 相似文献
34.
目的:探讨急性重症胆管炎患者的手术时机和死亡原因。方法:回顾性分析23例急性重症胆管炎患者的治疗及预后情况。结果:死亡2例(手术死亡及传统治疗死亡各1例)。早期大剂量短期应用糖皮质激素患者休克得到纠正率85%,明显高于未用糖皮质激素患者休克纠正率50%。结论:急性重症胆管炎患者应在出现休克和(或)精神症状之前手术,对已出现休克的患者,应先给予充分的保守治疗,待病情稳定后再手术。贻误手术时机,严重合并症如多器官功能衰竭及高龄是死亡的主要原因。 相似文献
35.
Jean Marie Jully Marie Christine Béné Gérard Martin Gilbert Faure 《Journal of clinical periodontology》1986,13(3):223-227
The cellular infiltrate present in human diseased gingiva was analyzed in biopsies from 12 patients with gingivitis or periodontitis. The samples studied had been obtained in the course of surgery at inflammatory sites remaining after institution of periodontal treatment. Histological and immunological techniques were used to identify macrophages, B-cells, plasma-cells, T-cells and T cell subsets, as well as cells expressing class II HLA membrane antigens. T-cells appeared as the predominant population, but plasma-cells were also visualized in nearly all samples. Both OKT4+ and OKT8+ cells were seen in all cases, the latter being more numerous in periodontitis patients. Interdigitating-like cells were observed, positively labelled for class II antigens, as well as macrophages which were more numerous in periodontitis patients. These results suggest the participation of all components of the immune response in gingival disease, in a way resembling chronic recurrent inflammatory diseases. 相似文献
36.
Judith D. Goldberg Arnold I. Weiss Kenneth J. Koury 《Journal of clinical periodontology》1986,13(5):411-414
In order to make effective use of the statistical theory of design of clinical trials for chronic diseases such as periodontal disease, certain issues must be considered. Any clinical trial requires that the disease definition be well-specified; that patient eligibility be explicit; that the observation times be explicit; that the duration and endpoint of therapy be specified; that the duration of subsequent followup observation be specified; and that the unit of observation (e.g., tooth, set of teeth, patient) be defined. In a chronic disease, the potential biases that can readily be introduced by self-selection of patients who enter the trial and/or who return for subsequent observation become more important, because subjects are required to remain on treatment and/or observation for prolonged periods. Further, the cyclical nature of some chronic diseases may require special attention to baseline definitions of active disease and disease outcome. These issues are illustrated with examples from clinical trials of hypertension, breast cancer screening, and Polycythemia Vera. Implications for periodontal disease are discussed. 相似文献
37.
The choice of therapies for Crohn's disease has expanded greatly over the past 30 years. Increasingly it is important that we attempt to identify subgroups of patients who will benefit most from each type of therapy. This article reviews the therapeutic options currently available, organized by the goal the practitioner hopes to achieve. Imaging is one critical way of aiding the classification of Crohn's disease by attempting to accurately determine the location, extent and, most importantly, the nature of the disease. 相似文献
38.
39.
Chronic headaches are difficult to treat and represent the biggest challenge in headache centres. Mirtazapine has a prophylactic and ibuprofen an acute effect in tension-type headache. Combination therapy may increase efficacy and lower side effects. We aimed to evaluate the prophylactic effect of a combination of low-dose mirtazapine and ibuprofen in chronic tension-type headache. Ninety-three patients were included in the double-blind, placebo-controlled, parallel trial. Following a 4-week run-in period they were randomized to four groups for treatment with a combination of mirtazapine 4.5 mg and ibuprofen 400 mg, placebo, mirtazapine 4.5 mg or ibuprofen 400 mg daily for 8 weeks. Eighty-four patients completed the study. The primary efficacy parameter, change in area under the headache curve from run-in to the last 4 weeks of treatment, did not differ between combination therapy (190) and placebo (219), P = 0.85. Explanatory analyses revealed worsening of headache already in the third week of treatment with ibuprofen alone. In conclusion, the combination of low-dose mirtazapine and ibuprofen is not effective for the treatment of chronic tension-type headache. Moreover, the study suggests that daily intake of ibuprofen worsens headache already after few weeks in chronic tension-type headache. 相似文献
40.